MBRXMoleculin Biotech, Inc.Signing up patients
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 312 (planned)
- Started
- Mar 12, 2025
- Main results expected
- Aug 2029
- Fully finished
- Aug 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A -Determination of Optimal Dosage Regimen
Measured over: From initiation of the first randomized treatment cycle until the first post treatment bone marrow assessment, assessed up to Day 49
Part B - Expansion at Optimal Dosage Regimen
Measured over: From initiation of the first randomized treatment cycle until the first post treatment bone marrow assessment, assessed up to Day 49
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06788756 · record last updated 2026-08-05 · checked 2026-11-09 15:47 UTC